Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) EBIT: 2013-2025

Historic EBIT for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to -$188.0 million.

  • KalVista Pharmaceuticals' EBIT rose 5.46% to -$45.8 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$171.6 million, marking a year-over-year decrease of 66.17%. This contributed to the annual value of -$188.0 million for FY2025, which is 33.86% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported EBIT of -$188.0 million as of FY2025, which was down 33.86% from -$140.4 million recorded in FY2024.
  • Over the past 5 years, KalVista Pharmaceuticals' EBIT peaked at -$57.9 million during FY2021, and registered a low of -$188.0 million during FY2025.
  • Its 3-year average for EBIT is -$146.4 million, with a median of -$140.4 million in 2024.
  • Data for KalVista Pharmaceuticals' EBIT shows a maximum YoY plummeted of 66.80% (in 2022) over the last 5 years.
  • Over the past 5 years, KalVista Pharmaceuticals' EBIT (Yearly) stood at -$57.9 million in 2021, then slumped by 66.80% to -$96.6 million in 2022, then dropped by 14.76% to -$110.9 million in 2023, then decreased by 26.67% to -$140.4 million in 2024, then slumped by 33.86% to -$188.0 million in 2025.